Dr Janine Mansi’s publications

Publications


111. Janine L. Mansi1, Ann Yellowlees2, Julian Lipscombe3, Helena M. Earl4, David A. Cameron5, Robert E. Coleman6, Timothy Perren7, Christopher J. Gallagher8, Mary Quigley9, John Crown10, Alison L. Jones11, Martin Highley12, Robert C.F. Leonard13, T.R. Jeffry Evans14 on behalf of the Anglo-Celtic Cooperative Oncology Group. Five-year outcome for women randomised in a Phase III trial comparing doxorubicin and cyclophosphamide with


Manuscripts in preparation

1. Pickering LM, Mansi JL, Colston KW. Zoledronic acid impairs the adhesion of breast cancer cell lines to mineralised matrices.

Research participation resulting in published manuscripts (not exhaustive)


4 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005 Jan 1; 365(9453):60-2.


6 azure study

Chapters and editorials


**Invited speaker (not exhaustive)**

9. Mansi JL. Endocrine therapy in advanced breast cancer. 3rd Palliative Care Course, Charing Cross Hospital, November 1989.
25. Mansi JL. Adjuvant Chemotherapy and Endocrine Treatment for Breast Cancer. Postgraduate Certificate/Diploma in Breast Diagnosis, Module 5 Breast cancer treatment and palliative care. Faculty of Health and Social Care Sciences, St George’s Hospital Medical School. June 2002.

Published oral and poster presentations (not exhaustive)


8. Jodrell DI, Mansi JL, Ashley SE et al. A randomised comparison of mitzantrone, methotrexate and mitomycin C (MMM) and cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first line chemotherapy (CT) for advanced breast cancer. ECCO, September 1989. poster


11. Mansi JL. Navelbine in combination chemotherapy in advanced breast cancer. UICC, August 1990. oral


15. Mansi JL et al. ECF: A highly active regimen in gastric carcinoma. European Society of Medical Oncology 1990 Copenhagen. oral


35. Judson IR, Talbot DC, Smith IE, Graham MA, Tierney KL, Mansi JL, Calvert AH, Foster BJ. Cardiotoxicity of the anthrapyrazole C1941, not due to free radical formation. AACR 1991. poster


58. Oakley, CM, Mansi, JL. The implementation of a home chemotherapy service - a collaborative project between hospital end community. European Journal of Cancer 1995 31A (S5): P1324.poster


76. Lofts FJ, Thompson F, Mansi JL. A phase I dose escalation of hydroxyurea in addition to continuous infusion 5-fluorouracil in patients with advanced colorectal cancer. Poster


100. Evans TRJ, Yellowlees A, Foster L, Mansi JL. 2004 Adriamycin and Taxotere compared with Adriamycin and Cyclophosphamide as primary medical therapy in breast cancer. Am Soc Clin Oncol June


108. Pickering LM, MacDonald CD, Mansi JL, Colston KW. Bisphosphonates induce apoptosis and inhibit adhesion to mineralised matrix in breast and lung carcinoma cell lines. International Conference on Cancer-Induced Bone Disease, Bethesda, USA 2005

110. Pickering LM, Macdonald CD, Mansi JL, Colston KW. Bisphosphonates induce apoptosis and inhibit adhesion to mineralised matrix in lung carcinoma cell lines. World Lung Congress, Barcelona 2005

111. Evans TR Jeffry, Yellowlees Ann, Devine Irene, Earl Helena, Cameron David A, Hutcheon Andrew W, Coleman Robert E, Crown John, Leonard Robert C F, Mansi Janine L on behalf of the Anglo-Celtic Co-operative Oncology Group. To compare the disease-free (DFS) and overall survival (OS), at a median follow up of 80 months, of women with primary or locally advanced breast cancer randomised to receive either doxorubicin and cyclophosphamide (AC) or doxorubicin and docetaxel (AD) as primary chemotherapy. ASCO 2008.


113. S. Ghosh; M Van Hemelrijck; CD Holdridge; JF Gibson; PJ Ross; J Mansi; R Lal; PA Ellis; PG Harper; S Chowdhury. How accurate is clinician reporting of chemotherapy side-effects? A prospective study comparing clinician with patient-reported symptoms. ASCO 2010 Abs 48920